Introduction
Neurofibromatosis type 1 (NF1), also referred to as von Recklinhausen syndrome, is a common cancer predisposition syndrome caused by loss of the NF1 gene (Gutmann, 2001; Zhu and Parada, 2002) . NF1 is characterized by the formation of benign neurofibromas, composed primarily of Schwann cells, and plexiform neurofibromas, which can sporadically transform into malignant peripheral nerve sheath tumors (MPNSTs; also known as neurofibrosarcomas). NF1 patients also have an increased brain size due to increased numbers of astrocytes and an increased risk for developing optic pathway gliomas, pheochromocytomas and myeloid leukemias. The NF1 gene encodes neurofibromin, a tumor suppressor that possesses GTPase-activating protein (GAP) activity. Accordingly, NF1 loss results in elevated levels of activated Ras. The conversion of benign neurofibromas to malignant cancer is not fully understood, but is thought to require one or more additional genetic events such as the acquisition of mutations in the p53 and/or Ink4a genes (Menon et al., 1990; Cichowski et al., 1999; Kourea et al., 1999; Vogel et al., 1999; Birindelli et al., 2001) .
The Notch proteins comprise a family of transmembrane receptors that regulate cell-fate decisions during metazoan development (Artavanis-Tsakonas et al., 1999) . Mammals express four Notch receptors and at least six membrane-associated ligands. Notch signaling within a cell usually requires one or more of the receptors and expression of a ligand by an adjacent cell. Notch proteins are found on the cell surface as proteolyzed heterodimers, and binding of ligand renders them susceptible to two additional proteolytic cleavages, culminating in the release of the respective Notch intracellular domains, NICDs, from the plasma membrane. The released NICDs enter the nucleus and activate transcription through interactions with Mastermind and the DNA-binding protein CSL Fryer et al., 2002; Jeffries et al., 2002; Wallberg et al., 2002) .
Notch signaling regulates a variety of binary cell fate choices, including the choice of lymphoid progenitors to become either B cells or T cells (Allman et al., 2002) and neural crest-derived progenitors to become either neurons or glia (Wang and Barres, 2000) . Notch signaling is incompatible with the development of B cells and neurons, while promoting the development of T cells and certain types of glia, including Schwann cells (Morrison et al., 2000) , astrocytes (Tanigaki et al., 2001) , radial glia (Gaiano et al., 2000) and Mu¨ller glia (Furukawa et al., 2000) . Interestingly, Notch inhibits the differentiation of oligodendrocytes, a glial cell type found within the CNS (Wang et al., 1998) . In patients with multiple sclerosis, the inflammatory cytokine TGFb induces expression of the Notch ligand Jagged1 in actrocytes residing within sclerotic lesions. This is thought to activate Notch signaling in neighboring oligodendrocytes and thus block their ability to mature and to myelinate axons (John et al., 2002) .
Although Notch signaling typically serves to regulate cell fate choice, unbridled signaling can also lead to cancer. The latter outcome is highly cell type specific and generally correlates with constitutive, ligand-independent expression of NICD. Examples of Notch-induced neoplasias include T-cell lymphomas (human (Ellisen et al., 1991) and mouse (Girard et al., 1996; Pear et al., 1996) ), pancreatic cancer (mouse and human (Miyamoto et al., 2003) ), mammary epithelial cell tumors (mouse (Jhappan et al., 1992) ), and the transformation -in collaboration with the Adenovirus E1a protein -of cultured rat embryonic epithelial cells (Capobianco et al., 1997) . Notch signaling may also be required for Rasmediated transformation of human cells (Weijzen et al., 2002) . While downstream components of the Notch signaling cascade that govern cell fate choice have been well described -such as the manner in which Notch inhibits fly neurogenesis -virtually nothing is known about the pathways that promote neoplastic transformation. Notch signaling is not universally mitogenic, and so transformation may be linked to other activities, such as the inhibition of apoptosis, as has been described for T lymphocytes (Deftos et al., 1998; Jehn et al., 1999) , or the neutralization of growth-inhibitory pathways, such as that induced by TGF-b (Rao and Kadesch, in press ). Conceivably, Notch may also transform cells by stalling differentiation at a point coincidentally associated with cell proliferation.
We looked for evidence of Notch signaling in Schwann cell lines derived from human MPNSTs. One of the three cell lines expressed cleaved Notch (NICD) and an elevated level of the Notch target Hes-1, indicating the presence of an active Notch signaling cascade. In support of an oncogenic role for Notch in human Schwann cells, we found that forced expression of NICD induced malignant transformation of rat Schwann cells.
Results

Notch signaling in Schwann cells derived from a human MPNST
The conversion of benign plexiform neurofibromas to malignant peripheral nerve sheath tumors (MPNSTs) in NF1 patients is likely to involve one or more additional genetic events. Although mutations in the p53 and Ink4a genes have been described, these mutations are not universally present in NF1-derived MPNSTs (Menon et al., 1990; Kourea et al., 1999; Birindelli et al., 2001) . Also, while mouse models support a strong collaborative relationship between NF1 and p53 mutations, functional studies of the relevant pathways have not been carried out in human cells. We therefore examined the p53 pathway in four Schwann cell lines, one derived from a benign neurofibroma (NF) (Rutkowski et al., 2000) and three from MPNSTs (sNF94.3, sNF02.2 and sNF96.2) (Muir et al., 2001) . Cells were treated with increasing doses of the DNA-damaging agent adriamycin, which induces the expression of p53 and its target p21 in wild-type cells. We found that adriamycin induced expression of p53 in a dose-dependent manner in all the four human cell lines (Figure 1 , top panel). p21 was also induced in all the four cell lines, but more efficiently at the lower doses of adriamycin ( Figure 1 , lower panel). The lower levels of p21 observed when the human cells were treated with higher doses of adriamycin were unexpected, but could possibly be due to DNA damage-induced apoptosis. Although the basal level of p21 was relatively high in the sNF96.2 line, it was clearly induced relative to Cdk4. We conclude that the p53 pathway, most likely including the sequestration of MDM2 by p19 ARF , is largely intact in these Schwann cell lines.
Notch has been implicated in Ras-mediated transformation of human cells (Weijzen et al., 2002) . Given that elevated Ras is elevated as a consequence of mutations in neurofibromin and therefore almost certainly required in MPNSTs, we examined the Schwann cell lines for evidence of Notch signaling. A reliable method for assessing whether or not a cell is undergoing Notch signaling is to determine if the cells express endogenous cleaved Notch (NICD). When cell extracts were analysed by Western immunoblotting using an antibody specific for endogenous NICD (see Materials and methods), a positive signal was observed for the sNF96.2 MPNST Schwann cells, and no signal was detected for the other cell lines (Figure 2 , upper panel). Given that this antibody recognizes the Notch intracellular domain only after it is cleaved at Val1744, a positive signal indicates appropriate cleavage by gsecretase and the generation of transcriptionally active NICD. Consistent with this observation, RT-PCR analyses showed increased expression of the Notch target gene Hes-1 in the sNF96.2 cells relative to the others ( Figure 2 , center panel). Another Notch target, Hes-5, was not detected in any of the human cell lines (data not shown). The high basal level of p21 in the sNF96.2 cells may also be a consequence of Notch signaling, since the p21 promoter has been shown to be a direct Notch target in keratinocytes (Rangarajan et al., 2001b) . The presence or absence of endogenous NICD did not vary with cell density, suggesting that Notch activity in these cells did not result from ligand-mediated activation. We conclude that the sNF96.2 Schwann cell line was derived from an MPNST undergoing active Notch signaling, raising the possibility that Notch contributed to its conversion to malignancy. The generation of NICD generally requires a g-secretasedependent cleavage event, even if NICD is generated constitutively (Weng et al., 2003) . In support for a causal role for NICD in the transformed nature of sNF96.2 cells, treatment with a g-secretase inhibitor significantly impaired cell proliferation (data not shown). Whether or not Notch activation is a common occurrence in MPNSTs will require the generation and evaluation of additional Schwann cell lines.
NICD induces morphological changes in rat Schwann cells associated with the extinction of differentiation markers
To investigate the direct effect of Notch signaling in mature Schwann cells, we transduced cultured rat cells with a retrovirus that encodes the intracellular domain of human Notch1 (NICD) (Ross and Kadesch, 2001) or a control virus (MigR1) (Pear et al., 1998) . Both viruses express GFP, which was used as a marker for infected cells. Transient transfections with a Notch-responsive reporter confirmed the activity of the transduced NICD (data not shown). Significant morphological changes were observed in virtually 100% of the NICD-transduced (i.e. GFP-positive) cells. Unlike the parental or MigR1-transduced cells, which grew as elongated, spindle-shaped monolayers, the NICD-transduced cells formed foci of small, rounded cells (a typical example is shown in Figure 3) .
We next examined the NICD-transduced cells for changes in gene expression. When viral transduction efficiencies were high, we were able to analyse a highly enriched population without purification. As judged by Western blotting, the NICD-transduced cells expressed NICD (primers were designed to detect human Notch) and higher levels of Hes-5, a known Notch/CSL target gene (Figure 4a ) (de la Pompa et al., 1997; Beatus et al., 1999) . The protein corresponding to another Notch target, Hes-1 (Jarriault et al., 1995) , was detected in the parental and MigR1-transduced cells, and was not significantly increased in the presence of NICD. In this regard, the rat cells differ from the human cells which express NICD and Hes-1, but not Hes-5. We speculate that transcription factors other than NICD influence expression of the Hes genes. Interestingly, the NICDtransduced cells lost expression of several Schwann cellspecific markers. Western immunoblot analysis showed that the level of the myelin protein P 0 was dramatically reduced in the presence of NICD, as were p75 NGF receptor and GFAP (Figure 4b ). RT-PCR analyses also showed a decreased level of P 0 mRNA as well as message corresponding to ErbB3. RNA corresponding to Sox-10, a glia-promoting transcription factor that promotes the expression of the myelin P 0 and ErbB3 genes (Stolt et al., 2002) , was also reduced in NICDtransduced cells (Figure 4c ). We considered two explanations for these results: either NICD caused the Schwann cells to actively de-differentiate, or NICD expression is stable only in a subpopulation of undifferentiated Schwann cells present in the original pool of cells. We favor the former explanation, since we do not observe an appreciable fraction of cells with the morphology of NICD-transduced cells in the absence of NICD retroviral transduction.
NICD transforms rat Schwann cells
The morphology of the NICD-transduced Schwann cells was reminiscent of transformed cells that are not contact inhibited. Indeed, NICD-transduced Schwann cells, but not parental or MigR1-transduced cells, were able to form colonies in soft agar (data not shown). An analysis of specific cell cycle markers ( Figure 5a ) showed dramatically elevated levels of the Cyclins A, D1 and D2 in the NICD-transduced cells. Cdk2 levels were slightly higher, while the level of Cdk4 was unchanged.
Levels of the Cdk inhibitory proteins p15
INK4b and p27 were not affected by NICD. The level of phosphorylated ERK, diagnostic of increased Ras-MAPK signaling, was also elevated in the NICD-transduced cells. Finally, induction of p53 and its target p21 by adriamycin was unaffected by NICD (Figure 5b ). Overall, these data indicate that NICD has appreciable effects on the critical components of the cell cycle in Schwann cells, consistent with cellular transformation.
To determine if the aforementioned changes involved true oncogenic transformation, we assessed the ability of NICD-transduced cells to generate tumors in rats. Roughly one million cells, representing pools of either NICD-transduced or MigR1-transduced cells, were injected subcutaneously at three spots on the nape of nude rats. Tumors developed in three of three rats injected with NICD-transduced Schwann cells (at all three spots), but not in rats injected with control Schwann cells (data not shown). The tumors reached a diameter of 0.5-1 cm after 2 weeks, and 2-2.5 cm after 1 month. Fluorescence microscopy confirmed that the tumor cells were all GFP positive (data not shown). The tumors were highly vascular and the cells had a small, round morphology, reminiscent of a primitive neuroectodermal tumor (Figures 6a and b) . These results indicate that expression of NICD in Schwann cells can induce transformation and generate cells capable of growing as tumor masses. 
Discussion
In humans, activated Notch has been implicated as a causal agent in T-cell lymphoma (Notch1; Ellisen et al., 1991) and pancreatic cancer (Miyamoto et al., 2003) . Notch has also been shown to induce or to accelerate the development of T cell (Girard et al., 1996; Pear et al., 1996) and mammary epithelial neoplasias in mice (Jhappan et al., 1992) . In most cases, normal regulation of Notch is disrupted -through chromosomal translocation, provirus insertion or viral transduction -leading to constitutive expression of NICD. Despite these examples, Notch's ability to act as an oncogene is highly cell type specific and poorly understood. Retroviral transduction of hematopoietic precursors in mice results only in T-cell tumors; B-cell development is blocked and other cell types are relatively unaffected (Pui et al., 1999) . Somewhat conflicting results indicate that Notch proteins cooperate with Papilloma virus genes to transform epithelial cells (Rangarajan et al., 2001a) , but that Notch1, specifically, must be downregulated for sustained expression of the viral oncogenes (Talora et al., 2002) . The specific deletion of Notch1 in mouse skin results in an increased frequency of tumors, implicating Notch1 as a tumor suppressor in that context (Nicolas et al., 2003) . Similarly, abrogating Notch activity in NIH 3T3 cells promotes FGFdependent cellular transformation (Small et al., 2003) . However, since FGF acts as a mitogen for rat Schwann cells (Davis and Stroobant, 1990) , it is unlikely that Notch acts as a general antagonist of FGF signaling. While certain aspects of Notch's oncogenic effects can be mimicked in cultured cells, the mechanisms underlying these effects, including their cell type specificity, are largely unknown. Salivary gland tumors carrying the t(11;19)9q21;p13) translocation express a novel fusion protein containing the Notch coactivator MAML2 (Tonon et al., 2003) . Although this strongly implicates the Notch pathway in salivary gland tumorigenesis, the MECT1-MAML2 fusion protein activates gene expression independently of CSL, thereby suggesting the existence of a noncanonical signaling pathway for these Notch-induced tumors.
Here we show that Notch can transform primary Schwann cells in vitro. The only other example of Notch-induced transformation of cultured cells involves rat embryo kidney (RKE) cells, but that requires cooperation with the adenovirus E1A gene (Capobianco et al., 1997) . The reasons underlying the ability of Notch to function alone to transform Schwann cells are not known, but may be related in part to the observed increase in cyclin expression, a result that was also reported in the RKE system (Ronchini and Capobianco, 2001) . Despite this apparent disruption in cell cycle control, Notch does not appear to be acting as a mitogen per se. Our transformed cells do not grow more rapidly than the parental cells, and they will overtake a dish containing untransduced cells only if the cells are allowed to grow beyond confluency, conditions that favor cells whose growth is not subject to contact inhibition (SJv, unpublished observations). A somewhat related alteration in growth characteristics has been described for Notch4-transduced mammary epithelial cells, which acquire an invasive phenotype when grown on collagen gels (Soriano et al., 2000) . This particular alteration has been proposed to be important for Notch4's ability to induce mammary tumors in mice.
Transformation by NICD is associated with the loss of Schwann cell differentiation markers. Perhaps, the most significant of these is Sox10, a transcription factor expressed in neural crest cells and necessary for the terminal stages of glial cell development (Britsch et al., 2001; Stolt et al., 2002) . However, this raises a paradox. How can Notch signaling be required in vertebrate gliogenesis, as has been described for multiple glial cell types including Schwann cells, yet repress expression of a gene necessary for Schwann cell development? This cannot be attributed to the high-level expression of activated Notch in our experiments -similar retroviral vectors promote the formation of both Mu¨ller glia and radial glia in the CNS (Furukawa et al., 2000; Gaiano et al., 2000) . It is more likely that the precise target cell determines the ultimate consequences of Notch activity, and we have targeted NICD to differentiated Schwann cells, as opposed to undifferentiated precursors. Moreover, Notch signaling inhibits the formation of oligodendrocytes, indicating that the effect of Notch on gliogenesis is not universal (Wang et al., 1998) . Notch signaling has also been correlated with the inability of oligodendrocytes to mature and myelinate nerves within the CNS of patients with multiple sclerosis (John et al., 2002) . Our studies with Schwann cells raise the possibility that inappropriate Notch signaling within the CNS may also initiate demyelination by causing oligodendrocytes to dedifferentiate.
The ability of NICD to transform Schwann cells is interesting, and by itself provides a useful in vitro model system to study Notch-mediated oncogenesis. However, we have also provided evidence that activated Notch is induced in a human NF1 MPNST. Although the present sample size is small due to the difficulty in purifying and culturing Schwann cells from MPNSTs, the identification of a cell line that expresses activated Notch suggests that at least one case of malignant transformation is associated with constitutive Notch signaling. Such signaling could be due to a chromosomal translocation involving one of the four Notch genes (leading to ligandindependent NICD expression; Ellisen et al., 1991) or to high-level expression of a Notch ligand that induces signaling in neighboring cells (despite the presence of NICD in subconfluent cultures). It will be very important to learn the frequency with which Notch is activated in MPNST and, depending on the underlying cause, if Notch inhibition might provide an effective treatment.
Materials and methods
Schwann cell lines
Rat Schwann cells were isolated from the sciatic nerves of 2-day-old rat pups using the method described by Brockes et al. 1979) . The cells were maintained in DMEM supplemented with 10% heat-inactivated fetal bovine serum. Rat Schwann cells were expanded using 2 mM forskolin and 25 ng/ml recombinant glial growth factor. At 1 week prior to the analyses of cells, both forskolin and glial growth factor were removed. Passage-matched Schwann cells were infected with the parental, GFP-expressing MigR1 retrovirus (Pear et al., 1998) , or the NICD-and GFP-expressing retrovirus (Ross and Kadesch, 2001) . When needed, transduced cells were purified by FACS using GFP as a marker. The human cell lines sNF94.3, sNF96.2 and sNF02.2 were established using methods described previously (Muir et al., 2001) . All specimens included in this study were obtained in accordance with the protocols approved by the University of Florida IRB. Originative tumors were characterized as malignant peripheral nerve sheath tumors (neurofibrosarcoma) by histopathology, and were obtained from patients meeting the NF1 diagnostic criteria. Tumor pieces were minced and dissociated for 3-5 h with dispase (1.25 U/ml; Collaborative Research) and collagenase (300 U/ml; type XI, Sigma) in L15 medium containing 10% calf serum and antibiotics. The digested tissue was dispersed by trituration and strained through a 30-mesh nylon screen. Collected cells were seeded on laminin-coated dishes and grown in DMEM containing 10% fetal bovine serum, 5% calf serum, glial growth factor-2 (25 ng/ml) and antibiotics. Cultures were subsequently grown and rapidly expanded without laminin and glial growth factor-2. The three immortal cell lines had spindle-shaped morphology and were immunopositive for S-100 and faintly for p75 (low-affinity nerve growth factor receptor), indicating Schwann cell lineage. They were subsequently grown in DMEM containing 10% heat-inactivated fetal bovine serum.
Western immunoblotting
Cells were washed and then lysed in RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% NP40, 0.5% DOC, 0.1% SDS, 1 mM PNPP, 20 nM calyculin A, 1 mM Na Vanadate, 1 mM phenylmethylsulfonylfluoride, 1 mg/ml leupeptin, 10 mg/ml aprotinin). Lysates were collected, clarified by centrifugation for 15 min at 41C, resolved by PAGE and transferred to nitrocellulose membranes. Typically, the membranes were then incubated with the primary antibody at 41C overnight, followed by horseradish peroxidase-conjugated secondary antibody (1 : 10 000 dilution, Amersham Pharmacia Biotech, Cleveland, OH, USA) at room temperature for 1 h. Bands were visualized by an enhanced chemiluminescence (ECL) detection system (Amersham Pharmacia Biotech) or Lumilight Plus (Roche, Indianapolis, IN, USA). Adriamycin was from Bedford Laboratories (Bedford, OH, USA). Rabbit antibody against cleaved Notch1/NICD (val1744) was obtained from Cell Signaling Technology (Beverly, MA, USA). Note that the specificity of this antibody is such that it does not recognize the Notch intracellular domain unless it has been appropriately cleaved. Antibodies against b-tubulin and p53 were from Sigma (St Louis, MO, USA) and Novacastra Laboratories, Ltd (New Castle, UK), respectively. Antibodies against Cyclin D1, Cyclin D2, CDK2, CDK4, p21, p27, Cdk4, Jagged-1, Notch1, GFAP and Erb B2 were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The antibody against MRE11 was from Novus Biologicals (Littleton, CO, USA). Rabbit anti-P 0 antibody was provided by Dr Bruce Trapp (Cleveland Clinic, OH, USA). Rabbit anti HES-1 and HES-5 antibodies were from Chemicon International (Temecula, CA, USA). Rabbit antibody against p75 was obtained from Promega (Madison, WI, USA).
RT-PCR
Total RNA (2 mg) was used to obtain cDNA by reverse transcription using RETROscript first-strand synthesis kit (Ambion, Inc., Austin, TX, USA), and then subjected to PCR using 0.5 U/ml Amplitaq (Applied Biosytems, Foster City, CA, USA), as per the manufacturer's instructions, using the following conditions: 90 s at 941C, 45 s at 941C, 45 s at 591C, 
Tumorigenicity assays
Tumorigenicity assays were performed by injecting 10 6 cells (in 100 ml PBS) subcutaneously into nude rats. The cells were injected at three sites on the nape of 8-9-week-old female Athymic nude rats. The rats were monitored twice weekly and killed after 30 days (when a tumor of 2-2.5 cm diameter was apparent). Tumor tissue was fixed in PBS containing 4% paraformaldehyde and embedded in paraffin. Tissue sections were stained with hematoxylin/eosin for the examination of tumor structure by light microscopy.
